From Keith Edwards, MD May 26, 2017 With the news of a MS patient in Germany who developed PML after 3 years of Tysabri and then one dose of ocrelizumab, the question of effectiveness and safety in ‘sequencing’ or switching from Tysabri (natalizumab) to another MS medication has become an even more important decision. What… Read more »
Dr. Edwards will be attending the 2017 American Academy of Neurology meeting in Boston, MA April 22-28. He is the author/co-author on several posters & platform sessions at AAN (Click here for accepted posters). The AAN Annual Meeting is the world’s largest gathering of neurologists, bringing together more than 10,000 neurology professionals across the globe to… Read more »
Dr. Edwards mentioned in the clip below regarding news on OCREVUS™ .
Current available management of MS can now limit, stop or improve disability for the majority of patient with MS. The management needs to be appropriate, safe and effective to be of value. No longer is it acceptable to continue a failed treatment. Management and treatment begin with good general health from diet and exercise to… Read more »